The ACR applauds the FTC’s recent ban on most noncompete agreements. The ruling is a step in the right direction toward a more competitive market for healthcare workers and their services.
Commercial Payers Update Reimbursement for Underwater Infliximab Biosimilars
Three commercial health insurance payers have increased reimbursement for infliximab biosimilars in response to concerns that formulary requirements are leaving practices underwater.
Congressional Action Partially Addresses Medicare Cuts
The newest funding package reduces the latest cut to Medicare reimbursement from 3.4% to 1.68%. Although rheumatologists are faring better under Medicare in 2024, broader reforms remain the ACR’s highest priority regarding Medicare payments to physicians.
RheumPAC’s Role in the ACR’s Advocacy Efforts
In an election year, it is critical that the ACR’s non-partisan political action committee be well positioned to support our congressional champions. Learn more about RheumPAC and its role in the ACR’s advocacy efforts.
Updates from the ACR Insurance Subcommittee
The Insurance Subcommittee is working to address coverage and reimbursement challenges facing rheumatology practices, including issues related to biosimilar use, in-office treatments and the new G2211 code.
The Biosimilar Economic Conundrum: Where We Stand
Reimbursement has fallen below acquisition price for some biosimilar versions of infliximab, forcing practices and patients to make difficult decisions. The ACR is working to change this.
ACR Advocacy Staff Outline Victories, Challenges from a Busy Year
SAN DIEGO—In an advocacy update session at ACR Convergence 2023, ACR staff described progress in multiple priority areas, including access to care and workforce issues.
CMS Proposes Reimbursement Cuts for CY24
On July 13, the Centers for Medicare and Medicaid Services released the CY 2024 Medicare Physician Fee Schedule Notice of Proposed Rulemaking. This annual rule outlines policies related to provider reimbursement, coverage of telehealth services, review of specific codes, refinement of evaluation and management codes and updates to the Quality Payment Program.
Copay Accumulator & Maximizer Programs Threaten Access to Treatment
As health insurance companies and third-party benefit managers continue to use copay accumulators and maximizers to shift the cost of specialty drugs to patients, the ACR continues to advocate against programs that limit copay assistance.
Rheumatology Priorities Advanced at Busy AMA House of Delegates Meeting
Two ACR-led resolutions on in-office specialty drug dispensing and the proposed NIH Public Access Plan passed the House of Delegates and will become AMA policy.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 10
- Next Page »